1. Home
  2. JLS vs RPID Comparison

JLS vs RPID Comparison

Compare JLS & RPID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen Mortgage and Income Fund

JLS

Nuveen Mortgage and Income Fund

HOLD

Current Price

$17.58

Market Cap

100.6M

Sector

Finance

ML Signal

HOLD

Logo Rapid Micro Biosystems Inc.

RPID

Rapid Micro Biosystems Inc.

HOLD

Current Price

$2.06

Market Cap

85.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JLS
RPID
Founded
2009
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
100.6M
85.7M
IPO Year
2009
2021

Fundamental Metrics

Financial Performance
Metric
JLS
RPID
Price
$17.58
$2.06
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$8.00
AVG Volume (30 Days)
26.1K
221.2K
Earning Date
01-01-0001
05-08-2026
Dividend Yield
9.33%
N/A
EPS Growth
N/A
2.78
EPS
N/A
N/A
Revenue
N/A
$33,587,000.00
Revenue This Year
N/A
$19.12
Revenue Next Year
N/A
$18.42
P/E Ratio
N/A
N/A
Revenue Growth
N/A
19.74
52 Week Low
$17.29
$1.66
52 Week High
$19.09
$4.94

Technical Indicators

Market Signals
Indicator
JLS
RPID
Relative Strength Index (RSI) 48.93 59.98
Support Level $17.41 $2.04
Resistance Level $18.66 $2.17
Average True Range (ATR) 0.16 0.14
MACD 0.04 0.04
Stochastic Oscillator 68.75 73.28

Price Performance

Historical Comparison
JLS
RPID

About JLS Nuveen Mortgage and Income Fund

Nuveen Mortgage And Income Fund is a diversified, closed-end management investment company. The fund invests at least fifty percent of its Managed Assets in MBS, including residential MBS and commercial MBS, and up to fifty percent in non-mortgage related ABS. The Fund's investment objective is to provide a high level of current income.

About RPID Rapid Micro Biosystems Inc.

Rapid Micro Biosystems Inc is a life sciences technology company. Its technology uses a sensitive camera and the natural autofluorescence of living cells to identify and quantify microbial growth faster and more accurately than the traditional method, which relies on the human eye. The company develops, manufactures, markets, and sells Growth Direct systems (Systems), proprietary consumables, laboratory information management system (LIMS) connection, and other software and services to address rapid microbial analysis used for quality control in the manufacture of pharmaceuticals, medical devices, and personal care products. Geographically, it generates maximum revenue from the United States, and the rest from Switzerland, Germany, Japan, and all other countries.

Share on Social Networks: